Insulet Corporation (NASDAQ: PODD) — 2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017. This is an annual filing, not a standalone fourth-quarter report. Financial amounts below are in U.S. dollars.
Business context
Insulet develops, manufactures and sells the Omnipod tubeless insulin delivery system and customized drug-delivery devices. Omnipod sales are made directly and through distributors in the U.S. and internationally. Drug-delivery revenue is primarily tied to Amgen’s Neulasta Onpro kit.
Key financial results
| Metric | FY 2017 | FY 2016 | Change |
|---|---|---|---|
| Revenue | $463.8 million | $367.0 million | +26% |
| Gross profit / margin | $277.2 million / 59.8% | $211.1 million / 57.5% | Margin +2.3 percentage points |
| Operating loss | $7.4 million | $10.7 million | Loss narrowed |
| Net loss | $26.8 million | $28.9 million | Loss narrowed |
| Operating cash flow | $41.2 million | $15.9 million | Increased |
| Capital expenditures | $77.2 million | $22.1 million | Increased, principally for Acton facility |
- Revenue by category: U.S. Omnipod $271.6 million (+18%); international Omnipod $120.0 million (+67%); drug delivery $72.2 million (+11%).
- Fourth-quarter 2017 revenue was $130.5 million, gross profit $79.5 million, operating loss $0.8 million and net loss $6.9 million. In Q4 2016, revenue was $103.6 million, gross profit $60.9 million, operating loss $4.1 million and net loss $9.1 million.
- At year-end, cash and cash equivalents were $272.6 million, short-term investments $167.5 million, and long-term investments $125.5 million. Working capital was $451.1 million.
- Convertible-note principal outstanding was $751.2 million; balance-sheet debt, net of discount and issuance costs, was $566.2 million. Notes mature from 2019 to 2024. Cash interest obligations disclosed for 2018 were $9.9 million.
- Gross margin improvement reflected supply-chain efficiencies, partly offset by a less favorable mix from higher European distributor sales. The company remained loss-making, with an accumulated deficit of $707.3 million.
Material changes and management outlook
- Revenue rose 26%, led by international Omnipod growth. Operating expenses increased 28% to $284.6 million, including higher R&D, sales and marketing, and administrative spending.
- Management expects strong 2018 revenue growth and higher gross margin, citing continued U.S. and international expansion and the planned move to direct European distribution. It expects higher operating expenses in 2018 and net losses in the near term.
- Insulet plans to assume European sales, distribution, training and support on July 1, 2018, after the Ypsomed agreement expires. Management expects direct distribution to improve average European pricing and, after transition costs, be accretive; execution, customer retention and added costs are risks.
- The Acton, Massachusetts automated manufacturing facility is expected to begin production in early 2019. Insulet had invested about $70 million by year-end and expects total facility capital expenditures to approach $200 million by production startup.
- In January 2018, CMS clarified that Medicare Part D plans may cover products such as Omnipod. Insulet estimates potential Medicare and Medicaid access for approximately 450,000 additional people with Type 1 diabetes, but coverage depends on plan and state decisions.
- Insulet submitted a 510(k) application for its DASH system in January 2018; commercial release is contingent on FDA clearance. Development programs also include concentrated-insulin products and a hybrid closed-loop system.
Risks, contingencies and unusual items
- Insulet relies on Flex’s China facility for finished Omnipod systems and identifies supplier disruption, manufacturing quality, capacity and cost control as significant risks.
- Three customers represented more than 10% of annual revenue: Ypsomed 22%, Amgen 15% and RGH Enterprises 11%. Ypsomed also represented 31% of accounts receivable at year-end.
- Following the European distribution transition, Insulet expects a per-unit fee for qualifying sales to certain existing Ypsomed customers over 12 months. The estimated total range is approximately $10 million to $55 million; the amount depends on qualifying sales.
- A securities class action and two related derivative suits were disclosed. The company reached an agreement in principle to settle the class action, subject to court approval; the expected uninsured liability accrued was described as immaterial. Alternative exposure was not estimable if approval is denied.
- In November 2017, Insulet issued $402.5 million of 1.375% convertible notes due 2024 and used proceeds, in part, to repurchase $63.4 million principal amount of 2.0% notes due 2019.
- The company reported no off-balance-sheet financing arrangements. Its U.S. deferred tax assets remain subject to a full valuation allowance; the Tax Cuts and Jobs Act produced a provisional tax benefit of approximately $0.3 million.
Important facts for investors to verify
- Progress on Medicare Part D formularies and state Medicaid coverage, including timing and realized patient access.
- FDA review and clearance timing for DASH, and development milestones for concentrated-insulin and automated glucose-control products.
- Execution, costs, customer retention and the $10 million to $55 million potential Ypsomed transition fee as direct European operations begin.
- Acton facility construction schedule, total cost, production ramp and whether manufacturing efficiencies improve gross margin.
- Debt maturities and refinancing or repayment plans, given $751.2 million of note principal and ongoing operating losses.
- Customer and supplier concentration, including Ypsomed’s revenue and receivables exposure and reliance on the Flex-operated China manufacturing site.
- Final court approval and terms of the securities class-action settlement.